About: COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation
Creator	Rengan, Ramesh Chen, Jonathan Fang, L Chino, Junzo Dunn, Emily »more»
source	Elsevier; Medline; PMC
abstract	PURPOSE: The purpose of this study was to highlight the importance of timely brachytherapy treatment for patients with gynecologic, breast, and prostate malignancies, and provide a framework for brachytherapy clinical practice and management in response to the COVID-19 pandemic. METHODS AND MATERIALS: We review amassing evidence to help guide the management and timing of brachytherapy for gynecologic, breast, and prostate cancers. Where concrete data could not be found, peer-reviewed expert opinion is provided. RESULTS: There may be a significant negative impact on oncologic outcomes for patients with gynecologic malignancies who have a delay in the timely completion of therapy. Delay of prostate or breast cancer treatment may also impact oncologic outcomes. If a treatment delay is expected, endocrine therapy may be an appropriate temporizing measure before delivery of radiation therapy. The use of shorter brachytherapy fractionation schedules will help minimize patient exposure and conserve resources. CONCLUSIONS: Brachytherapy remains a critical treatment for patients and may shorten treatment time and exposure for some. Reduced patient exposure and resource utilization is important during COVID-19. Every effort should be made to ensure timely brachytherapy delivery for patients with gynecologic malignancies, and endocrine therapy may help temporize treatment delays for breast and prostate cancer patients. Physicians should continue to follow developing institutional, state, and federal guidelines/recommendations as challenges in delivering care during COVID-19 will continue to evolve.
has issue date	2020-04-21(xsd:dateTime)
bibo:doi	10.1016/j.brachy.2020.04.005
bibo:pmid	32359937
has license	no-cc
sha1sum (hex)	0a9cafd7b271164aee46f199e31d652d5b29da8a
schema:url	https://doi.org/10.1016/j.brachy.2020.04.005
resource representing a document's title	COVID-19 impact on timing of brachytherapy treatment and strategies for risk mitigation
has PubMed Central identifier	PMC7172676
has PubMed identifier	32359937
schema:publication	Brachytherapy
resource representing a document's body	covid:0a9cafd7b271164aee46f199e31d652d5b29da8a#body_text
is schema:about of	named entity 'prostate cancer' named entity 'measure' named entity 'impact' named entity 'prostate' named entity 'gynecologic' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software